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Background: Cholinesterase inhibitors are used to treat the symptoms of dementia and can theoretically cause
bradycardia. Previous studies suggest that patients taking these medications have an increased risk of undergoing
pacemaker insertion. Since these drugs have a marginal impact on patient outcomes, it might be preferable to
change drug treatment rather than implant a pacemaker. This population-based study determined the association
of people with dementia exposed to cholinesterase inhibitor medication and pacemaker insertion.
Methods: We used data from the Ontario health administrative databases from January 1, 1993 to June 30, 2012.
We included all community-dwelling seniors who had a code for dementia and were exposed to cholinesterase
inhibitors (donezepil, galantamine, and rivastigmine) and/or drugs used to treat co-morbidities of hypertension,
diabetes, depression and hypothyroidism. We controlled for exposure to anti-arrhythmic drugs. Observation started
at first exposure to any medication and continued until the earliest of pacemaker insertion, death, or end of study.
Results: 2,353,909 people were included with 96,000 (4.1%) undergoing pacemaker insertion during the
observation period. Case–control analysis showed that pacemaker patients were less likely to be coded with
dementia (unadjusted OR 0.42 [95%CI 0.41-0.42]) or exposed to cholinesterase inhibitors (unadjusted OR 0.39
[95%CI 0.37-0.41]). That Cohort analysis showed patients with dementia taking cholinesterase inhibitors had a
decreased risk of pacemaker insertion (unadj-HR 0.58 [0.55-0.61]). Adjustment for patient age, sex, and other
medications did not notably change results, as did restricting the analysis to incident users.
Conclusions: Patients taking cholinesterase inhibitors rarely undergo, and have a significantly reduced risk of,
cardiac pacemaker insertion.
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The population in most countries is aging. The propor-
tion of people aged 65-years and older constituted 15%
of the Canadian population in 2011, higher than at any
other time in our history [1]. Cognitive impairment
affects a significant portion of older adults with an
incidence of more than 25% in those 90-years old [2].
Cholinesterase inhibitors (donepezil, rivastigmine and
galantamine) have become accepted as one of the few
therapeutic interventions available that can improve the
quality of life for those patients with this condition [3-5].
Given this, and the aging population, the prevalence of
these medications in medical care will increase.
Cholinesterase inhibitor medications can cause a
cholinergic excess that can result in non-specific symp-
toms including gastrointestinal upset, diarrhea, and
muscle cramps. These effects can theoretically also
cause bradycardia by increasing vagal tone. The inci-
dence of cardiac conduction abnormalities in the done-
pezil drug monograph is 1-2%. Several case reports
[6-9] have suggested a link between cholinesterase in-
hibitor use and bradycardia.
Five studies using health administrative data have mea-
sured the association of cholinesterase inhibitors and
conduction abnormalities. Park-Wyllie et. al. used a
case–control design to study 161 patients (0.59% of the
study population) who were exposed to cholinesterase
inhibitors and had an emergency room visit or
hospitalization coded with bradycardia [10]. Compared
to a control group, they found that the odds of having
bradycardia were 2.1 times higher with cholinesterase in-
hibitor exposure [10]. Using a cohort design, Hernandez
et. al. found that the risk of diagnosing bradycardia
(either in- or out-patient) was 40% higher in demented
patients exposed to cholinesterase inhibitors [11].
However, Kroger et. al. found no significant association
between hospitalization rates for either syncope or
atrioventricular block and either rivastigmine or galan-
tamine exposure [12]. Gill’s study of 81,302 patients
coded with dementia, who had syncopal events, found
a similar probability of pacemaker insertion (0.3%
each) but significantly higher pacemaker insertion
rates in patients exposed to cholinesterase inhibitors (4.7
vs. 3.3 events per 1000-person years, HR 1.49; 95% CI,
1.12-2.00) [13].
Given the modest clinical impact of cholinesterase in-
hibitors on patient outcomes [14], it is important to de-
termine the population-based impact of cholinesterase
inhibitors on new or worsening bradycardia resulting in
pacemaker insertions. If pacemakers are being inserted
for side-effects of these drugs, a careful risk-benefit ana-
lysis is necessary for each patient in which the potential
risk of discontinuing the cholinesterase inhibitor medi-
ation needs to be compared to the potential risks andbenefits of pacemaker implantation and follow-up. To
determine how often cholinesterase inhibitors might
be triggering pacemaker insertion, we conducted this
population-based study to determine the association of
exposure to cholinesterase inhibitor medication and
pacemaker insertion.
Methods
Data sources for the study
The population of Ontario in 2011 was 13.3 M people,
of which 14.6% or 1.9 M were 65-years and older. This
study used population-based health administrative data-
bases in Ontario, Canada in which the costs for all
hospital and physician services are covered by a universal
health care system. Databases used in this study included:
Ontario Drug Benefits Database (ODBD), which captures
all prescriptions of drugs for seniors that are covered by
the provincial drug plan; Discharge Abstract Database
(DAD), which captures all hospitalizations and day sur-
geries; National Ambulatory Care Reporting System
(NACRS), which captures all emergency room visits;
Ontario Health Insurance Plan (OHIP) which captures
all claims for physician services; and Registered Persons
Database (RPDB), which captures each person’s date of
death. All databases were linked deterministically via
encrypted health care numbers. The study was approved
by The Ottawa Hospital Research Ethics Board. No
identifying information was used or extracted during
the linkage processes so individual informed consent
was not required.
Study cohort
This study included all people in the province of
Ontario, Canada who were older than 65-years between
January 1, 1993 and June 30, 2012, were living in the
community, and; i) had at least one claim in DAD,
NACRS, or OHIP with a diagnostic code for dementia
(see Table 1); or ii) were dispensed at least one of the
study drugs during this time period. Codes found in
health administrative databases have been shown to have
high specificities for diagnostic conditions [15]; and the
codes we used to identify dementia patients were the
same as those used in previous studies [13,16]. Exposure
to any of the study drugs was determined using the
ODBD with medications included in this study limited
to those listed in ODBD. The primary study drugs in-
cluded the cholinesterase inhibitors donezepil, galanta-
mine, and rivastigmine. Donepezil was approved for use
in Ontario in 1996–97 and prescribers had to record a
‘limited use’ code in order for the cost of the medication
to be subsidized by the Ontario Drug Benefit program.
We also included several comparison drugs (defined as
those that we would not expect to directly influence
pacemaker insertion risk) to which the association of
Table 2 List of comparison medications
Class Medications






















Proton pump inhibitors Lansoprazole
Omeprazaole
Pantoprazole












Table 1 Diagnostic codes used to determine the presence
of dementia in study databases
Code Description
ICD10
F00 Dementia in Alzheimer’s disease
F01 Vascular dementia
F02 Dementia from Pick’s, Creutzfeldt-Jakob, Huntington’s,




290 Senile dementia, presenile dementia
3310 Alzheimer’s disease
3311 Pick’s disease
3312 Senile degeneration of the brain
2912 Alcoholic dementia
2941 Dementia in other diseases
ICD = International Classification of Diseases, standardized coding versions
9 & 10.
ICD10 codes were used in DAD and NACRS after 2002. ICD9 codes were used
prior to 2002 and in the OHIP database. Since OHIP only captures the first 3
numbers of the ICD9 code, only 290 was used to identify dementia in
this dataset.
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could be compared. The comparison medications would
also represent a crude proxy of common co-morbidities
in older adults such as hypertension, diabetes, depres-
sion and hypothyroidism. These comparison drugs are
expected to have no direct cardiac conduction effect on
the risk on pacemaker insertions. The comparison drugs
(see Table 2 for details) included: angiotensin converting
enzyme-inhibitors (ACE-inhibitors); angiotensin recep-
tor blockers; insulin or oral anti-glycemics; histamine-2
(H2) receptor blockers; proton pump inhibitors; selective
serotonin reuptake inhibitors; statins; thiazide diuretics;
and thyroxine. Finally, we included several controlling
drugs which included any medication that might inter-
fere with the cardiac conduction system. These included
Vaughan Williams [17] antiarrhythmic drug classes listed
in Table 3.
Exposure to each drug started on the date of its first
dispensation. In the default analysis, we included all
prescriptions (i.e. both incident and prevalent). We used
the prescription dosage and the drug’s usual administra-
tion frequency to calculate the expected duration of the
medication. Drug use was considered to be continuous
if the next prescription for the drug (or any other mem-
ber of that drug class) occurred within 120 days follow-
ing (i.e. at the end of ) the previous prescription. If no
subsequent prescription occurred, we assigned the end
of exposure as 60 days following the prescription start
date.Outcome
The study’s primary outcome was pacemaker insertion.
This was determined by linking to DAD to identify any
subsequent encounter in which a pacemaker insertion was
coded (Canadian Classification of Diagnostic, Therapeutic
and Surgical Procedures codes 49.7, 49.71, 49.72, 49.73, or
51.64; Canadian Classification of Health Interventions
Table 3 Vaughan Williams anti-arrhythmic drug classes
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cluded any surgical type (i.e. we did not restrict outcomes
to those classified as primary). Patients were excluded
from the analysis if a pacemaker had been inserted prior
to the start of their observation. Figure 1 shows a sche-
matic of the selection of the study cohorts.
Analysis
We used two analytical methods to determine the in-
dependent association of cholinesterase inhibitors with
pacemaker insertion. The first analysis was a nestedFigure 1 Schematic of the study cohort selection.case–control analysis in which we found four control
patients from our cohort for each pacemaker insertion.
The greedy matching algorithm [18] was used to match
controls by age (within 5 years) and sex. We then con-
ducted univariate and multivariate conditional logistic
regression to determine the unadjusted and adjusted
association of cholinesterase inhibitor use and pace-
maker insertion, respectively [19].
In the second analysis, we used proportional-hazards
modeling to determine the association of exposure to
cholinesterase inhibitors with time to the insertion of
pacemakers independent of patient age or sex and ex-
posure to any of the other medications. In this analysis,
observation started with the earliest date of a code for
dementia or the prescription of any study drug. Obser-
vation ended with the earliest of: pacemaker insertion;
patient death (as determined by linking to RPDB); or
study end (30 June 2012). The diagnosis of dementia
and all medication exposures were expressed as time-
dependent covariates in the proportional hazards model.
The model describes a continuous exposure to cholin-
esterase inhibitors at the time of pacemaker insertion.
Results
Between 1 January 1993 and 30 June 2012, there were
2,446,105 Ontarians older than 65 years of age that had
a code for dementia or were prescribed one or more
study drugs. 29,744 people (1.2%) had a pacemaker
inserted prior to entering the cohort and were excluded,
leaving 2,353,909 people in the study. These people had
a mean age of 72 years and 56.0% were women (Table 4).
A quarter of the study cohort had a code for dementia
(N = 607,540; 25.8%). Of these people, 184,945 (30.4%)
were treated with cholinesterase inhibitors. Additionally,
93.9% of people treated with cholinesterase inhibitors
had a code for dementia. More than half of the cohort
was exposed (at one time during the observation
period) to ace-inhibitor/angiotensin receptor blockers
(52.7%) and proton-pump inhibitors/H2-receptor blockers
(55.8%).
Table 4 Description of study patients






Mean age years (95% confidence interval) 72.1 (72.0, 72.1) 72.1 (72.1, 72.1) 71.6 (71.6, 71.7)
Male 1,036,044 (44.0) 981,569 (43.5) 54,475 (56.7)
Had a code for dementia 607,540 (25.8) 576,114 (25.5) 31,426 (32.7)
MEDICATION GROUP EXPOSURE
At any time
Cholinesterase inhibitor 197,021 (8.4) 186,366 (8.3) 10,655 (11.1)
Ace-inhibitor / Angiotensin receptor blocker 1,239,438 (52.7) 1,167,268 (51.7) 72,170 (75.2)
Insulin / oral hypoglycemic agent 420,699 (17.9) 397,520 (17.6) 23,179 (24.1)
Proton pump inhibitors/H2-receptor blocker 1,313,173 (55.8) 1,249,276 (55.3) 63,897 (66.6)
Selective serotonin reuptake inhibitor 522,474 (22.2) 495,830 (22.0) 26,644 (27.8)
Statin 904,123 (38.4) 850,149 (37.7) 53,974 (56.2)
Thiazide diuretic 697,510 (29.6) 661,058 (29.3) 36,452 (38.0)
Thyroxine 338,349 (14.4) 317,760 (14.1) 20,589 (21.4)
Vaughan-Williams drug class
Ia 12,494 (0.5) 10,853 (0.5) 1,641 (1.7)
Ib 2,046 (0.1) 1,738 (0.1) 308 (0.3)
Ic 23,917 (1.0) 19,679 (0.9) 4,238 (4.4)
II (beta-blockers) 834,007 (35.4) 770,077 (34.1) 63,930 (66.6)
III 87,435 (3.7) 68,858 (3.0) 18,577 (19.4)
IV (calcium channel blockers) 387,964 (16.5) 356,840 (15.8) 31,124 (32.4)
V (digoxin) 332,370 (14.1) 299,183 (13.3) 33,187 (34.6)
Median proportion observation time exposed
to medication group (25th,75th %ile)
Cholinesterase inhibitor 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
Ace-inhibitor/Angiotensin receptor blocker 0.01 (0.00-0.22) 0.01 (0.00-0.22) 0.03 (0.00-0.26)
Insulin/oral hypoglycemic agent 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
Proton pump inhibitors/H2-receptor blocker 0.01 (0.00-0.09) 0.01 (0.00-0.09) 0.00 (0.00-0.05)
Selective serotonin reuptake inhibitor 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
Statin 0.00 (0.00-0.08) 0.00 (0.00-0.08) 0.00 (0.00-0.08)
Thiazide diuretic 0.00 (0.00-0.02) 0.00 (0.00-0.02) 0.00 (0.00-0.01)
Thyroxine 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
Vaughan-Williams drug class
Ia 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
Ib 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
Ic 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
II (beta-blockers) 0.00 (0.00-0.04) 0.00 (0.00-0.04) 0.01 (0.00-0.15)
III 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
IV (calcium channel blockers) 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.01)
V (digoxin) 0.00 (0.00-0.00) 0.00 (0.00-0.00) 0.00 (0.00-0.00)
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patient-years (median 5.5 years, IQR 1.8-10.44 years).
Most of this time was spent without exposure to any of
the study drugs. For example, the median proportionof observation time that each patient spent exposed to
any particular study drug was 0 except for ace-
inhibitors/angiotensin receptor blockers (with a median
proportion of time exposed of 0.01) and proton-pump
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portion of time exposed of 0.01). The 75th percentile for
the proportion of time exposed to study drugs was 0 for
all drugs except ACE-inhibitors/angiotensin receptor
blockers (0.22), proton-pump inhibitors/H2-receptor
antagonists (0.09), statins (0.08), thiazides (0.02), and
beta-blockers (0.04).
96,000 people (4.1%) underwent pacemaker insertion
during the study. Compared to those without insertion,
pacemaker patients were notably more likely to be male
(Table 4) and were much more likely to be exposed (at any
time during their observation period) to ACE-inhibitors
or angiotensin receptor blockers, statins, beta-blockers,
amiodarone, calcium channel blockers, and digoxin.
Case–control analysis
All people having a pacemaker inserted during the study
were successfully matched to a total of 382,112 controls.
Matching was highly successful with an identical propor-
tion of patients being male (56.7%) and an identical
mean age at the end of observation (78.2 years, SD 6.7)
in both cases and controls. Cases (i.e. those undergoing
pacemaker insertion) were notably less likely to be coded
with dementia (10.9% vs. 22.8%; unadjusted odds ratio
(OR) 0.42 [95%CI 0.41-0.42]) or exposed to cholinester-
ase inhibitors (1.6% vs. 4.0%; unadjusted OR 0.39
[95%CI 0.37-0.41]) (Table 5). Most other medicationsTable 5 Case–control analysis determining the association of
Medication Pacemaker





Had a code for dementia 10488 (10.9) 87460
Cholinesterase inhibitor 1530 (1.6) 15055
Ace-inhibitor/Angiotensin receptor blocker 19536 (20.4) 70672
Insulin/oral hypoglycemic agent 6416 (6.7) 28900
Proton pump inhibitors/H2-receptor blocker 8054 (8.4) 55903
Selective serotonin reuptake inhibitor 2591 (2.7) 25525
Statin 12746 (13.3) 53896
Thiazide diuretic 4138 (4.3) 24407
Thyroxine 4353 (4.5) 18660
Vaughan-Williams drug class
Ia 272 (0.3) 352 (0.1
Ib 41 (0) 74 (0)
Ic 907 (0.9) 840 (0.2
II (beta-blockers) 15770 (16.4) 38904
III 3614 (3.8) 3939 (1
IV (calcium channel blockers) 6291 (6.6) 15501
V (digoxin) 7965 (8.3) 17815
CI = Confidence interval.
This is a case–control analysis in which cases and controls were matched based on
incident user analysis excluded exposures in patients who were already taking thehad significant but small associations with pacemaker in-
sertion with several notable exceptions: selective serotonin
reuptake inhibitor exposure was notably less common in
pacemaker patients (unadjusted OR 0.39 [0.37-0.41]);
pacemaker patients were notably more likely to be ex-
posed to antiarrhythmic agents, Vaughan Williams class
1a (OR 3.10, 2.64-3.63), class 1b (OR 2.22,1.51-3.25), class
1c (OR 4.35,3.96-4.78), and class III (OR 3.77,3.61-3.95).
Unadjusted odds ratios did not change importantly in
either the adjusted model or the adjusted incident user
model (Table 5).
Cohort analysis
This analysis included the entire cohort (N = 2,353,909).
1.7% patients coded with dementia and 0.8% of patients
taking cholinesterase inhibitors had a pacemaker inserted
after the code was assigned and while exposed to the drug,
respectively (Table 6). Pacemakers were inserted in smaller
proportions of people taking proton pump inhibitors/
H2-receptor antagonists (0.6%), selective serotonin re-
uptake inhibitors (0.5%), and thiazide diuretics (0.6%).
Pacemaker insertion was notably higher in those taking
Class Ic (3.8%) and Class III (4.1%) antiarrhythmic
medications.
The unadjusted proportional hazards model found that
both patients coded with dementia and those with
cholinesterase inhibitor exposure had a significantlypacemaker status with medication exposure
emaker









(22.8) 0.42 (0.41, 0.42) 0.41 (0.41, 0.42) 0.41 (0.4, 0.42)
(3.9) 0.40 (0.38, 0.42) 0.76 (0.76, 0.80) 0.75 (0.71, 0.79)
(18.4) 1.13 (1.11, 1.15) 0.99 (0.98, 1.00) 1.03 (1.01, 1.04)
(7.5) 0.88 (0.86, 0.91) 0.81 (0.81, 0.84) 0.83 (0.81, 0.86)
(14.6) 0.54 (0.52, 0.55) 0.51 (0.51, 0.52) 0.53 (0.52, 0.55)
(6.6) 0.39 (0.37, 0.41) 0.44 (0.44, 0.46) 0.45 (0.43, 0.47)
(14) 0.94 (0.92, 0.96) 0.84 (0.83, 0.85) 0.89 (0.87, 0.91)
(6.4) 0.66 (0.64, 0.69) 0.61 (0.61, 0.63) 0.64 (0.62, 0.66)
(4.9) 0.93 (0.90, 0.96) 0.88 (0.88, 0.91) 0.9 (0.87, 0.94)
) 3.10 (2.64, 3.63) 2.33 (2.29, 2.75) 2.38 (2, 2.82)
2.22 (1.51, 3.25) 1.47 (1.41, 2.20) 1.5 (0.99, 2.28)
) 4.35 (3.96, 4.78) 3.58 (3.54, 3.95) 3.66 (3.31, 4.05)
(10.1) 1.74 (1.71, 1.78) 1.60 (1.60, 1.63) 1.59 (1.56, 1.63)
) 3.77 (3.61, 3.95) 3.48 (3.46, 3.65) 3.47 (3.31, 3.65)
(4) 1.67 (1.62, 1.72) 1.49 (1.49, 1.54) 1.48 (1.43, 1.53)
(4.6) 1.86 (1.81, 1.91) 1.69 (1.69, 1.74) 1.67 (1.62, 1.72)
age and sex. The adjusted odds ratio adjusts for all covariates in the table. The
medication at study entry.







Incident and prevalent users Incident users only
HR 95% CI HR 95% CI HR 95% CI
Had a code for dementia 607,540 10,489 (1.7) 0.74 (0.72, 0.75) 0.83 (0.81, 0.85) 0.84 (0.82, 0.85)
Cholinesterase inhibitor 197,021 1530 (0.8) 0.58 (0.55, 0.61) 0.76 (0.72, 0.80) 0.75 (0.71, 0.79)
Ace-inhibitor/Angiotensin receptor blocker 1,239,438 19533 (1.6) 1.25 (1.23, 1.27) 1.22 (1.20, 1.24) 1.24 (1.22, 1.26)
Insulin/oral hypoglycemic agent 420,699 6415 (1.5) 1.04 (1.01, 1.07) 0.93 (0.91, 0.96) 0.93 (0.91, 0.95)
Proton pump inhibitors/H2-receptor blocker 1,313,173 8051 (0.6) 1.02 (1.00, 1.04) 1.12 (1.09, 1.14) 1.15 (1.12, 1.17)
Selective serotonin reuptake inhibitor 522,474 2591 (0.5) 0.71 (0.68, 0.74) 0.82 (0.79, 0.85) 0.82 (0.79, 0.86)
Statin 904,123 12745 (1.4) 1.22 (1.20, 1.25) 1.18 (1.16, 1.20) 1.20 (1.18, 1.23)
Thiazide diuretic 697,510 4138 (0.6) 0.79 (0.77, 0.81) 0.94 (0.91, 0.96) 0.95 (0.93, 0.98)
Thyroxine 338,998 4351 (1.3) 0.92 (0.90, 0.95) 0.91 (0.88, 0.94) 0.92 (0.89, 0.95)
Vaughan-Williams drug class
Ia 12,494 272 (2.2) 2.89 (2.58, 3.25) 2.25 (2.03, 2.48) 2.29 (2.07, 2.54)
Ib 2,046 41 (2.0) 2.71 (1.99, 3.68) 1.70 (1.30, 2.23) 1.74 (1.32, 2.30)
Ic 23,917 907 (3.8) 4.85 (4.56, 5.17) 4.11 (3.89, 4.35) 4.17 (3.93, 4.41)
II (beta-blockers) 834,007 15765 (1.9) 1.87 (1.84, 1.90) 2.13 (2.09, 2.16) 2.14 (2.11, 2.18)
III 87,435 3614 (4.1) 7.19 (6.96, 7.42) 8.32 (8.10, 8.54) 8.33 (8.11, 8.55)
IV (calcium channel blockers) 387,964 6291 (1.6) 1.46 (1.42, 1.50) 1.53 (1.50, 1.57) 1.53 (1.49, 1.57)
V (digoxin) 332,370 7962 (2.4) 2.50 (2.45, 2.56) 2.45 (2.39, 2.50) 2.44 (2.39, 2.50)
Other Factors
Age - - 1.00 (1.00, 1.01) 1.01 (1.01, 1.01) 1.00 (1.00, 1.01)
Male - - 2.03 (2.00, 2.05) 1.96 (1.93, 1.98) 1.96 (1.94, 1.99)
HR = Hazard ratio, CI = Confidence interval.
This analysis was conducted with unadjusted and adjusted proportional hazards regression models in which drug exposures were expressed using
time-dependent covariates. The incident user analysis excluded exposures in patients who were already taking the medication at study entry.
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0.74 [0.72-0.75] and 0.58 [0.55-0.61], respectively). The
latter was the lowest hazard ratio for pacemaker inser-
tion in all of the studied medications (Table 6). Overall,
results in the cohort analysis were similar to those from
the case–control analysis with a code for dementia or
cholinesterase inhibitor exposure independently associ-
ated with a decreased risk of pacemaker insertion; with
the risk in patients with both a code for dementia and
cholinesterase exposure being very low (adjusted HR
0.63). We saw significantly increased pacemaker risks
seen with each anti-arrhythmic medication (notably so
with class Ic and III medications). Adjustment for pa-
tient age, sex, and other medications did not notably
change results, as did restricting the analysis to incident
users (Table 6).
Discussion
Our population-based study found that the use of cho-
linesterase inhibitors did not increase the likelihood of
pacemaker insertion. While patients taking cholinester-
ase inhibitors do sometimes undergo pacemaker inser-
tion, our study found that this occurs in only 0.8% ofsuch patients and these medications are associated with
a decreased likelihood of this intervention. Although
anecdotal symptomatic bradycardia complicating cho-
linesterase inhibitor therapy could trigger pacemaker
implantation rather than drug suspension, our study
suggests that a theoretical cholinesterase inhibitor-
pacemaker cascade is unlikely.
We believe that the observed overall protective nature
of cholinesterase inhibitor exposure for pacemaker inser-
tion may be the result of a complex interaction between:
theoretical direct drug effects on the cardiac conduction
system; an indirect effect via a central nervous system
pathway; effects of a degenerative dementing illness on
cardiac rhythm; presence and effects of co-morbidities
not identified; altered symptom reporting or health-
seeking behaviour of people with dementia; and person,
family or health provider attitudes towards an invasive
intervention such as a cardiac pacemaker insertion. Data
for many of these factors are beyond the scope of this
study.
Another possibility to explain the lack of association
between cholinesterase inhibitor use and pacemaker in-
sertion is that in the years following the approval of
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cases have led to an increased awareness of the possible
development of bradycardia and resulted in a more
cautious approach to drug prescribing and symptom
management.
Our results compare interestingly with previous stud-
ies. Gill found a slightly higher risk of pacemaker inser-
tion (HR 1.49; 95% CI, 1.12-2.00) in demented patients
treated with cholinesterase inhibitors [13] who also
suffered a documented syncopal event. If the presence of
dementia decreases the likelihood of pacemaker inser-
tion, then cholinesterase inhibitor exposure in a study
including patients both with and without dementia
could be associated with a decreased risk of pacemaker
insertion. Our study extends the observation to ALL
demented patients who are exposed to cholinesterase
inhibitor drugs. Similar to previous studies, [20,21] we
found that patients taking amiodarone and/or digoxin
were significantly more likely to undergo pacemaker in-
sertion. This likely reflects the combination of complex
pharmacodynamics and the prevalence of ‘tachy-brady’
syndrome (i.e. atrial fibrillation with co-existent conduct-
ing system disease) in this population [22,23].
Our study has several attributes that should be con-
sidered when interpreting its results. First, ours is a
population-based analysis that captured all people ex-
posed to these medications in the Canadian province
with the largest population (13.3 M in 2011 [1]). This
lets us avoid errors associated with biased sampling.
Second, the data has face validity in that 30% of people
with dementia were being treated with a cholinesterase
inhibitor and almost all people (93.9%) prescribed a
cholinesterase inhibitor had a code for dementia. Third,
we used two analytical methodologies – case–control and
prospective cohort – to examine the association of cholin-
esterase inhibitor exposure and pacemaker insertion. The
fact that both analyses provided the same result supports
our conclusion. Fourth, we cannot be certain how
generalizable our results are to other jurisdictions. Al-
though our analysis includes a very large sample over a
long time-period, it is possible that subtleties native to
other health jurisdictions would change the association
between cholinesterase inhibitors and pacemaker in-
sertion. Fifth, we only included a patient’s first period
of exposure to a particular drug class. Patients who
stopped a medication for more than approximately 6-
months following dispensation would not have had the
subsequent exposure to these medications captured by
the study. Finally, dementia status and pacemaker
insertion were determined by codes. While these codes
have been shown in Medicare claims to have a sensitiv-
ity and specificity of 0.85 and 0.89, respectively [16],
the accuracy of dementia codes and those for pace-
maker insertion has not been confidently established inOntario administrative datasets. However, errors in the as-
signment of these codes would – assuming that such er-
rors are independent of cholinesterase status – bias the
study’s association to the null. When studying conditions
in older people, especially those who have multiple co-
morbidities, and are taking multiple medications and may
be classified as frail, caution has to be taken in assigning
associations. More research is needed to clarify the clinical
significance of the brady-arrhythmic effects of cholinester-
ase inhibitor drugs used to treat dementia.
Conclusions
In conclusion, our population-based analysis found that
patients taking cholinesterase inhibitors have a signifi-
cantly lower risk of pacemaker insertion. These results in-
dicate that scenarios whereby pacemakers are inserted to
treat side-effects of cholinesterase inhibitors do not appear
to play a meaningful role in pacemaker utilization in our
population.
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